OMDAHealthcare · Health Information ServicesOMDA Stock Forecast: Omada Health, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering Omada Health, Inc. hold a median 12-month price target of $27 — +29.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
OMDA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Omada Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Volatility (22): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Omada Health, Inc. — and when they’d sell — is the membership.
OMDA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OMDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +29.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $24 → $28 |
| 20 July 2026 | Citizens | Maintains | Market Outperform | $21 → $27 |
| 17 July 2026 | BTIG | Initiates | Buy | $30 |
| 22 June 2026 | Morgan Stanley | Reiterates | Overweight | $30 |
| 22 June 2026 | Morgan Stanley | Reiterates | Overweight | — |
| 8 May 2026 | Barclays | Maintains | Overweight | — |
| 8 May 2026 | Citizens | Maintains | Market Outperform | — |
| 8 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 8 May 2026 | Needham | Reiterates | Buy | — |
| 8 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 Apr 2026 | Citizens | Initiates | Market Outperform | — |
| 9 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 12 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 6 Mar 2026 | Barclays | Maintains | Overweight | — |
| 6 Mar 2026 | BMO Capital | Maintains | Outperform | — |
| 6 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
| 3 Mar 2026 | Barclays | Maintains | Overweight | — |
| 22 Jan 2026 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OMDA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Omada Health, Inc. (OMDA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −56.7×
- Price / sales
- 4.2×
- Price / book
- 5.0×
- EV / EBITDA
- −359.6×
Cheaper than 98% of US stocks
Cheaper than 30% of US stocks
Cheaper than 21% of US stocks
Cheaper than 98% of US stocks
- Revenue growth (YoY)
- 42.0%
- Earnings growth (YoY)
- 42.0%
- Gross margin
- 62.4%
- Operating margin
- −6.1%
- Net margin
- −2.2%
Higher than 85% of US stocks
Higher than 75% of US stocks
Higher than 77% of US stocks
Higher than 29% of US stocks
Higher than 27% of US stocks
- Return on equity
- −4.3%
- Return on assets
- −2.4%
- Dividend yield
- —
Higher than 40% of US stocks
Higher than 36% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OMDA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMDA appears on the weeks it earns a place.
Frequently asked questions about OMDA stock
What is the OMDA stock price forecast for 2026-2027?
The 12 Wall Street analysts covering Omada Health, Inc. have a median 12-month price target of $27, with estimates ranging from $15 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OMDA stock a buy right now?
Of the 12 analysts covering Omada Health, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omada Health, Inc. 85 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OMDA?
As at 1 Aug 2026, Omada Health, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
Will OMDA stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +29.2% from the last close, and Ticker Nerd's factor model ranks Omada Health, Inc. 85 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OMDA stock forecast for 2030?
No analyst covering Omada Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $30 over the next 12 months.
How has OMDA stock performed over the past year?
Omada Health, Inc. returned +18.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Omada Health, Inc. do?
Omada Health Inc. is a healthcare technology company specializing in virtual-first care programs focused on chronic disease prevention and management.
About Omada Health, Inc.
Omada Health Inc. is a healthcare technology company specializing in virtual-first care programs focused on chronic disease prevention and management. Founded in 2011 and headquartered in San Francisco, the company delivers digital solutions designed to support individuals in managing conditions such as diabetes, hypertension, and musculoskeletal disorders. Omada Health provides personalized care plans that combine human coaching, connected smart health devices, and interactive digital tools to guide members toward sustainable lifestyle changes. The company's services are tailored for employers, health plans, health systems, pharmacy benefit managers, and other organizations seeking to improve health outcomes and reduce long-term care costs. With a user-centric approach, Omada Health has served over a million members and collaborates with thousands of corporate partners across diverse sectors, including education, retail, and manufacturing. By leveraging data-driven insights and a multidisciplinary care team, Omada Health plays a pivotal role in the health information services sector, aiming to "bend the curve" of chronic disease through accessible, engaging, and effective virtual care solutions.
CEO Mr. Sean P. Duffy · 943 employees · United States · https://www.omadahealth.com